Related Experiment Video
Updated: Aug 17, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus
Ulrich-Peter Rohr1, Marc-Andre Wulf, Susanne Stahn
1Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany. urohr-uni-duesseldorf@gmx.de
Abstract:
In this study, we elucidated the potential of recombinant adeno-associated virus type-2 (rAAV-2) vectors for lung cancer gene therapy. Cell lines of the three major histological subtypes of non-small cell lung cancer (NSCLC) were highly susceptible for rAAV-2 showing transduction rates between 63.4 and 98.9%. In contrast, cell lines of small cell carcinomas were resistant to rAAV-2 infection. For restoration of p53 function in p53 deficient NSCLC, a rAAV-2 vector was constructed containing wt p53 cDNA. Following transduction with rAAV-p53, cell growth of all NSCLC cell lines was significantly reduced in a dose-dependent manner between 44 and 71.7% in comparison with rAAV-GFP transduced cells. The reduction of tumor cell growth was associated with increased apoptosis. Adding cisplatin to rAAV-p53-infected cells led to a significant growth inhibition between 81 and 91% indicating a synergistic effect between cisplatin and rAAV-p53. Interestingly, the tumor cells surviving cisplatin and rAAV-p53 treatment were inhibited in their ability to form colonies as reflected by a reduction of colony growth between 57 and 90.4%. In conclusion, rAAV-2 vectors exhibit a strong tropism for NSCLC. Successful inhibition of tumor cell growth following transduction with a rAAV-p53 vector underlines the potential role of rAAV-2 in cancer gene therapy.
Insights
Recombinant adeno-associated virus type-2 (rAAV-2) vectors show promise for non-small cell lung cancer (NSCLC) gene therapy. A rAAV-p53 vector effectively reduced NSCLC cell growth and enhanced cisplatin treatment efficacy.
Area of Science:
- Molecular Biology
- Oncology
- Gene Therapy
Background:
- Lung cancer remains a leading cause of cancer-related deaths globally.
- Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases.
- Gene therapy offers a potential alternative or adjunct to conventional cancer treatments.
Purpose of the Study:
- To investigate the efficacy of recombinant adeno-associated virus type-2 (rAAV-2) vectors for NSCLC gene therapy.
- To evaluate the potential of a rAAV-2 vector carrying wild-type p53 cDNA (rAAV-p53) in restoring p53 function and inhibiting tumor growth.
- To assess the synergistic effect of rAAV-p53 with cisplatin in NSCLC treatment.
Main Methods:
- Utilized cell lines representing major NSCLC histological subtypes.
- Transduced NSCLC cells with rAAV-2 vectors, including rAAV-p53 and a control rAAV-GFP.
- Assessed cell viability, apoptosis, and colony formation following treatment with rAAV-p53, alone and in combination with cisplatin.
Main Results:
- rAAV-2 demonstrated high transduction efficiency in NSCLC cell lines (63.4–98.9%), but not in small cell carcinoma lines.
- rAAV-p53 transduction significantly reduced NSCLC cell growth (44–71.7%) and induced apoptosis.
- Combination therapy with rAAV-p53 and cisplatin resulted in substantial growth inhibition (81–91%) and reduced colony formation (57–90.4%).
Conclusions:
- rAAV-2 vectors exhibit a strong tropism for NSCLC, making them suitable for targeted gene delivery.
- rAAV-p53 gene therapy effectively inhibits NSCLC cell proliferation and enhances chemosensitivity.
- These findings highlight the therapeutic potential of rAAV-2-based gene therapy for NSCLC treatment.
Related Concept Videos
02:23Abnormal Proliferation
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...